CYCLO THERAPEUTICS INC (CYTH)

US23254X2018 - Common Stock

1.39  -0.01 (-0.71%)

News Image
10 days ago - BusinessInsider

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclo Therapeutics (NASDAQ:CYTH) just reported results for the fourth quarter o...

News Image
10 days ago - InvestorPlace

CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023

Cyclo Therapeutics just reported results for the fourth quarter of 2023.

News Image
13 days ago - Chartmill

On Friday, there are stocks with unusual volume. Let's take a look.

Volume analysis on 2024-03-15: stocks with an unusual volume in today's session.

News Image
4 months ago - Rafael Holdings, Inc.

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments

News Image
5 months ago - Rafael Holdings, Inc.

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities

News Image
6 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPLK, CYTH, AMTI, EBC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
6 months ago - Seeking Alpha

Applied Molecular stock falls on merger with Cyclo Therapeutics

Applied Molecular Transport (AMTI) and Cyclo Therapeutics (CYTH) announced a merger agreement on Thursday whereby Applied Molecular (AMTI). Read more here.

News Image
10 months ago - Rafael Holdings, Inc.

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million